Updated Jul 16, 2026
Feeley Kevin has filed 4 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $5.62M.
Kevin Feeley is the Chief Financial Officer at GeneDx Holdings Corp, a company focused on delivering personalized health insights through genomic testing. He has been involved in 15 SEC filings related to his role, indicating active participation in the financial operations of the company.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-18 | WGS | GeneDx Holdings Corp. | S — Open-market sale | 863 | $61.50 | $53K |
| 2026-06-18 | WGS | GeneDx Holdings Corp. | S — Open-market sale | 2.1K | $60.83 | $128K |
| 2026-06-18 | WGS | GeneDx Holdings Corp. | S — Open-market sale | 760 | $59.75 | $45K |
| 2026-06-18 | WGS | GeneDx Holdings Corp. | M — Option exercise | 7.2K | $0.00 | |
| 2026-06-11 | WGS | GeneDx Holdings Corp. | S — Open-market sale | 1.3K | $53.77 | $68K |
| 2026-06-11 | WGS | GeneDx Holdings Corp. | M — Option exercise | 2.5K | $0.00 | |
| 2026-06-03 | WGS | GeneDx Holdings Corp. | S — Open-market sale | 369 | $51.74 | $19K |
| 2026-06-03 | WGS | GeneDx Holdings Corp. | M — Option exercise | 717 | $0.00 | |
| 2026-05-01 | WGS | GeneDx Holdings Corp. | S — Open-market sale | 392 | $65.19 | $26K |
| 2026-05-01 | WGS | GeneDx Holdings Corp. | M — Option exercise | 754 | $0.00 | |
| 2026-03-30 | WGS | GeneDx Holdings Corp. | S — Open-market sale | 1.9K | $65.21 | $121K |
| 2026-03-30 | WGS | GeneDx Holdings Corp. | S — Open-market sale | 995 | $64.60 | $64K |
| 2026-03-30 | WGS | GeneDx Holdings Corp. | S — Open-market sale | 2.5K | $63.28 | $159K |
| 2026-03-30 | WGS | GeneDx Holdings Corp. | S — Open-market sale | 961 | $62.33 | $60K |
| 2026-03-30 | WGS | GeneDx Holdings Corp. | S — Open-market sale | 2.5K | $61.29 | $152K |
| 2026-03-30 | WGS | GeneDx Holdings Corp. | M — Option exercise | 16.2K | $0.00 | |
| 2026-03-17 | WGS | GeneDx Holdings Corp. | S — Open-market sale | 257 | $77.94 | $20K |
| 2026-03-17 | WGS | GeneDx Holdings Corp. | S — Open-market sale | 3.1K | $77.05 | $236K |
| 2026-03-17 | WGS | GeneDx Holdings Corp. | S — Open-market sale | 2.4K | $76.35 | $182K |
| 2026-03-17 | WGS | GeneDx Holdings Corp. | M — Option exercise | 7.2K | $0.00 |
Kevin Feeley is the Chief Financial Officer at GeneDx Holdings Corp, a company focused on delivering personalized health insights through genomic testing. He has been involved in 15 SEC filings related to his role, indicating active participation in the financial operations of the company.…
4 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 48 open-market sales ($5.62M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Feeley Kevin profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.